Capivasertib: A Novel AKT Inhibitor Approved for Hormone-Receptor-Positive, HER-2-Negative Metastatic Breast Cancer.

Published in: The Annals of pharmacotherapy (2024)

Integration of capivasertib into clinical practice is ongoing; intermittent dosing and favorable toxicity are attractive for future novel combination prospective trials.

Keyphrases

metastatic breast cancer
clinical practice
signaling pathway
current status
cell proliferation
oxidative stress
high intensity
drug administration
oxide nanoparticles